Response-adaptive designs allow the randomization probabilities to change during the course of a trial based on cumulated response data so that a greater proportion of patients can be allocated to the ...
Early together: A randomized phase III study of early palliative care in metastatic uveal melanoma (MUM). Background: Anti-PD1-based immunotherapies have been approved for many cancer types and are ...
LARKSPUR, Calif.--(BUSINESS WIRE)--Global Coalition for Adaptive Research (GCAR), Sponsor of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) master protocol, announced that ...
SAN FRANCISCO--(BUSINESS WIRE)--OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced positive results from the recent Phase 2 study ...
Berry Consultants, LLC announced the release of FACTS 8, the latest version of its industry-leading Fixed and Adaptive Clinical Trial Simulator (FACTS). FACTS 8 is now available to both existing users ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback